Daclatasvir

Generic Details

Generic Name

Daclatasvir

Other Names

  • Daklinza

Drug Class

  • Antiviral

Chemical Formula

C40H50N8O6

Molecular Weight

738.89 g/mol

Mechanism of Action

  • Inhibitor of NS5A protein

Indications

  • Treatment of chronic hepatitis C virus (HCV) infection

Common Dosage Forms

  • Tablet

Typical Dosage

  • 60 mg once daily in combination with other antiviral medications

Pediatric Dosage

  • Not established

Geriatric Dosage

  • Adjust dosage based on renal function

Side Effects

  • Headache
  • Fatigue
  • Nausea
  • Insomnia
  • Anemia

Contraindications

  • Co-administration with strong CYP3A inhibitors or inducers

Pregnancy Category

  • Category B - Animal reproduction studies have failed to demonstrate risk to the fetus

Lactation Safety

  • Limited data available, use caution or avoid

Drug Interactions

  • Moderate to strong inducers or inhibitors of CYP3A may alter daclatasvir levels

Overdose Symptoms

  • Bradycardia
  • Syncope
  • Fatigue

Antidote for Overdose

  • Supportive care and monitoring

Storage Conditions

  • Store at room temperature below 30°C

Pharmacokinetics

  • Absorption: Rapid and high oral bioavailability
  • Distribution: Extensively distributed in the body
  • Metabolism: Primarily metabolized by CYP3A4 enzymes
  • Excretion: Eliminated mainly through feces

Precautions

  • Monitor liver function tests during treatment
  • Risk of bradycardia with concomitant use of certain medications

Warnings

  • Risk of hepatitis B reactivation
  • Risk of symptomatic bradycardia